English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  To conduct a patient‐level meta‐analysis of the  EDITION  1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml ( G la‐300) with insulin glargine 100 U/ml ( G la‐100) in people with type 2 diabetes ( T2DM ) on basal and mealtime insulin, basal insulin and oral antihyperglycaemic drugs, or no prior insulin, respectively.    Methods  The  EDITION  studies were multicentre, randomized, open‐label, parallel‐group, phase  IIIa  studies, with similar designs and endpoints. A patient‐level meta‐analysis of the studies enabled these endpoints to be examined over 6 months in a large population with  T2DM  ( G la‐300, n = 1247;  G la‐100, n = 1249).    Results  No significant study‐by‐treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated haemoglobin was comparable for  G la‐300 and  G la‐100 [each −1.02 (standard error 0.03)%; least squares ( LS ) mean difference 0.00 (95% confidence interval (CI) −0.08 to 0.07)%]. Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with  G la‐300 than with  G la‐100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of participants with ≥1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare ( G la‐300: 2.3%;  G la‐100: 2.6%). Weight gain was low (<1 kg) in both groups, with less gain with  G la‐300 [ LS  mean difference −0.28 kg (95% CI −0.55 to −0.01); p = 0.039]. Both treatments were well tolerated, with similar rates of adverse events.    Conclusion  Gla‐300 provides comparable glycaemic control to  G la‐100 in a large population with a broad clinical spectrum of  T2DM , with consistently less hypoglycaemia at any time of day and less nocturnal hypoglycaemia.

diabetes, obesity and metabolism

Patient‐level meta‐analysis of the  EDITION  1, 2 and 3  studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes